Silvia FRANCESCHELLI | Progetti

In 2023 we demonstrated how the Vx-809 corrector counteracts the activation of the UPR pathway by acting on protein folding on adeno-carcinomic human alveolar basal epithelial (A549) and malignant melanoma (A375) cells. Therefore, in this study, we would like investigated if the off-label mechanism of Vx-809 is also confirmed in a neuroblastoma cell model, hypothesizing that it interacts not only

Understanding the molecular and cellular basis of diseases is vital for dissecting the mechanisms of disease pathogenesis and for designing appropriate and effective treatments. Studying plants, their pathologies, their bioactive metabolites and how to improve their growth conditions is essential to find new drugs and to recommend correct lifestyles.

Demonstrate, in vitro, the Vx-809 ability to reduce the endoplasmic reticulum stress, induced by Thapsigargin, Tunicamycin and DETA NONOate, in lung adenocarcinoma (A549) and melanoma (A375) cells; in addition, characterize the hypothetical general role of corrector in protein processing.Evaluate if the sperimental protocol is valid also on neuronal cell lines, such as SH-SY5Y cells, used as cel

Da esperimenti condotti nel nostro laboratorio è stato osservato che il correttore Lumacaftor (Vx-809), efficace nel ripristinare il ripiegamento della proteina CFTR mutata e nell'incrementare la sua funzione di CFTR, potrebbe agire con un meccanismo generale sul folding proteico. L'obiettivo della ricerca sarà quello di valutare se in linee cellulari tumorali e normali, in cui è stato indotto unf

Attività di sostanze su cellule di tessuto nervoso”